364 related articles for article (PubMed ID: 30554729)
21. Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth.
Bloch J; Holzmann C; Koczan D; Helmke BM; Bullerdiek J
Oncotarget; 2017 May; 8(21):34762-34772. PubMed ID: 28410233
[TBL] [Abstract][Full Text] [Related]
22. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
[TBL] [Abstract][Full Text] [Related]
23. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
[TBL] [Abstract][Full Text] [Related]
24. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
25. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
26. MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas.
Zuberi A; Huang Y; Dotts AJ; Wei H; Coon JS; Liu S; Iizuka T; Wu O; Sotos O; Saini P; Chakravarti D; Boyer TG; Dai Y; Bulun SE; Yin P
JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37607000
[TBL] [Abstract][Full Text] [Related]
27. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
28. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
29. MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.
Markowski DN; Bartnitzke S; Löning T; Drieschner N; Helmke BM; Bullerdiek J
Int J Cancer; 2012 Oct; 131(7):1528-36. PubMed ID: 22223266
[TBL] [Abstract][Full Text] [Related]
30. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
Heinonen HR; Pasanen A; Heikinheimo O; Tanskanen T; Palin K; Tolvanen J; Vahteristo P; Sjöberg J; Pitkänen E; Bützow R; Mäkinen N; Aaltonen LA
Sci Rep; 2017 Apr; 7(1):1015. PubMed ID: 28432313
[TBL] [Abstract][Full Text] [Related]
31. Tryptophan catabolism is dysregulated in leiomyomas.
Chuang TD; Quintanilla D; Boos D; Khorram O
Fertil Steril; 2021 Oct; 116(4):1160-1171. PubMed ID: 34116832
[TBL] [Abstract][Full Text] [Related]
32. MED12 is frequently mutated in ovarian and other adnexal leiomyomas.
Li Z; Maeda D; Kudo-Asabe Y; Tamura D; Nanjo H; Hayashi A; Ikemura M; Fukayama M; Goto A
Hum Pathol; 2018 Nov; 81():89-95. PubMed ID: 29944972
[TBL] [Abstract][Full Text] [Related]
33. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma.
Ravegnini G; Mariño-Enriquez A; Slater J; Eilers G; Wang Y; Zhu M; Nucci MR; George S; Angelini S; Raut CP; Fletcher JA
Mod Pathol; 2013 May; 26(5):743-9. PubMed ID: 23222489
[TBL] [Abstract][Full Text] [Related]
34. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
[TBL] [Abstract][Full Text] [Related]
35. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
[TBL] [Abstract][Full Text] [Related]
36. MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors.
Markowski DN; Huhle S; Nimzyk R; Stenman G; Löning T; Bullerdiek J
Genes Chromosomes Cancer; 2013 Mar; 52(3):297-304. PubMed ID: 23225304
[TBL] [Abstract][Full Text] [Related]
37. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.
Mehine M; Kaasinen E; Heinonen HR; Mäkinen N; Kämpjärvi K; Sarvilinna N; Aavikko M; Vähärautio A; Pasanen A; Bützow R; Heikinheimo O; Sjöberg J; Pitkänen E; Vahteristo P; Aaltonen LA
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1315-20. PubMed ID: 26787895
[TBL] [Abstract][Full Text] [Related]
38. Screening of potential biomarkers in uterine leiomyomas disease via gene expression profiling analysis.
Liu X; Liu Y; Zhao J; Liu Y
Mol Med Rep; 2018 May; 17(5):6985-6996. PubMed ID: 29568968
[TBL] [Abstract][Full Text] [Related]
39. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
40. A mediator complex subunit 12 gain-of-function mutation induces partial leiomyoma cell properties in human uterine smooth muscle cells.
Takao T; Ono M; Yoshimasa Y; Masuda H; Maruyama T
F S Sci; 2022 Aug; 3(3):288-298. PubMed ID: 35643626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
